Effect of age and postoperative time on cytochrome P450 enzyme activity following liver transplantation

Journal of Clinical Pharmacology

Volumn 45, Issue 6, 2005, Pages 666-673

  Liu, Shanshan ^a   Frye, Reginald F ^b   Branch, Robert A ^c   Venkataramanan, Raman ^c   Fung, John J ^d   Burckart, Gilbert J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Age; Cytochrome P450; Liver transplantation; Phenotype

Indexed keywords

CAFFEINE; CHLORZOXAZONE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DAPSONE; DEBRISOQUINE; MEPHENYTOIN;

ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; HUMAN; LIVER FUNCTION; LIVER GRAFT; LIVER TRANSPLANTATION; MALE; PHENOTYPE; POSTOPERATIVE PERIOD; RECIPIENT;

AGED; CLINICAL TRIALS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; LIVER TRANSPLANTATION; MALE; PHENOTYPE; POSTOPERATIVE PERIOD; TIME FACTORS;

EID: 18844422136     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005276202     Document Type: Article

References (32)

1. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol. 2001;41:1149-1179.
2. Lewis DF. 57 varieties: the human cytochromes P450. Pharmacogenomics, 2004;5:305-318.
3. Chang GW, Kam PC. The physiological and pharmacological roles of cytochrome P450 isoenzymes. Anaesthesia. 1999;54(1):42-50.
4. Thorn M, Lundgren S, Herlenius G, Ericzon BG, Loof L, Rane A. Gene expression of cytochromes P(450) in liver transplants over time. Eur J Clin Pharmacol. 2004;60:413-420.
5. Mehta MU, Venkataramanan R, Burckart GJ, et al. Antipyrine kinetics in liver disease and liver transplantation. Clin Pharmacol Ther. 1986;39:372-377.
6. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther. 1997;62:365-376.
7. Burckart GJ, Frye RF, Kelly P, et al.: Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylation. Clin Pharmacol Ther. 1998;63:296-302.
8. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
9. Frye RF, Stiff DD, Branch RA. A sensitive method for the simultaneous determination of caffeine and its dimethylxanthine metabolites in human plasma: application to CYP1A2 phenotyping. J Liq Chrom Rel Tech. 1998;21:1161-1171.
10. Frye RF, Stiff DD. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996;686:291-296.
11. May DG, Porter JA, Uetrecht JP, Wilkinson GR, Branch RA. The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clin Pharmacol Ther. 1990;48:619-627.
12. Frye RF, Branch RA. Improved high-performance liquid chromatographic determination of debrisoquine and 4-hydroxydebrisoquine in human urine following direct injection. J Chromatogr B Biomed Appl. 1996;677:178-182.
13. Moreno JM, Cuervas-Mons V, Rubio E, et al. Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. Transplant Proc. 2003;35:1907-1908.
14. Facciuto M, Heidt D, Guarrera J, et al. Retransplantation for late liver graft failure: predictors of mortality. Liver Transpl. 2000;6:174-179.
15. Carcillo JA, Adedoyin A, Burckart GJ, et al. Coordinated intrahepatic and extrahepatic regulation of cytochrome p4502D6 in healthy subjects and in patients after liver transplantation. Clin Pharmacol Ther. 2003;73:456-467.
16. Bjoro K, Hockerstedt K, Ericzon BG, et al. Liver transplantation in patients over 60 years of age. Transpl Int. 2000;13(Suppl 1):S165-170.
17. Geokas MC, Haverback BJ. The aging gastrointestinal tract. Am J Surg. 1969;117:881-892.
18. Greenblatt DJ, Abernethy DR, Shader RI. Pharmacokinetic aspects of drug therapy in the elderly. Ther Drug Monit. 1986;8:249-255.
19. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992;44:275-283.
20. Simon T, Becquemont L, Hamon B, et al. Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers. Br J Clin Pharmacol. 2001;52:601-604.
21. Monek O, Paintaud G, Bechtel Y, Miguet JP, Mantion G, Bechtel PR. Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4. Eur J Clin Pharmacol. 1998;54:47-52.
22. Pan J, Xiang Q, Ball S. Use of a novel real-time quantitative reverse tianscription-polymerase chain reaction method to study the effects of cytokines on cytochrome P450 mRNA expression in mouse liver. Drug Metab Dispos. 2000;28:709-713.
23. Carcillo JA, Doughty L, Kofos D, et al. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med. 2003;29:980-984.
24. Tinel M, Elkahwaji J, Robin MA, et al. Interleukin-2 overexpresses c-myc and down-regulates cytochrome P-450 in rat hepatocytes. J Pharmacol Exp Ther. 1999;289:649-655.
25. Frye RF, Schneider VM, Frye CS, Feldman AM. Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail. 2002;8:315-319.
26. Abdel-Razzak Z, Loyer P, Fautrel A, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol. 1993;44:707-715.
27. Tindberg N, Baldwin HA, Cross AJ, Ingelman-Sundberg M. Induction of cytochrome P450 2E1 expression in rat and gerbil astrocytes by inflammatory factors and ischemic injury. Mol Pharmacol. 1996;50:1065-1072.
28. Park JM, Lin YS, Calamia JC, et al. Transiently altered acetaminophen metabolism after liver transplantation. Clin Pharmacol Ther. 2003;73:545-553.
29. Bendriss A, Bechtel Y, Paintaud G, et al. Stability of debrisoquine (CYP2D6) phenotype in liver transplant patients. Ther Drug Monit. 1995;17:113-119.
30. Gill HJ, Tingle MD, Park BK. N-hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Br J Clin Pharmacol. 1995;40:531-538.
31. Stein CM, Kinirons MT, Pincus T, Wilkinson GR, Wood AJ. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Clin Pharmacol Ther. 1996;59:47-51.
32. Gass RJ, Gal J, Fogle PW, Detmar-Hanna D, Gerber JG. Neither dapsone hydroxylation nor cortisol 6beta-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors. Eur J Clin Pharmacol. 1998;54:741-747.